|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection显示文摘AIM To identify the property of dendritic cella (DCs) of peripheral blood monocytes (PBMC) in patlents with chronic HBV infection.METHODS Twenty patients with persistent HBV infectlon were included in this study, 10 healthy subjects being used as a control group. The peripheral blood mononuclear cells (PBMC) of T cell-depleted populations were incubated and induced into mature dendritic cells in the RPMI-1640 medium in the presence of cytokines GMCSF, IL-4, FLt-3, TNF-α and 100 mL@ L-1 of fetal calf serum for a total of 10 - 12 days. The expressions of surface markers on DCs were evaluated using flow cytometric analysis. ELISA method was used to determine the cytokine levels of interleukin-12 (IL-12) and IL-10 in the supernatant produced by DCs. For detection of the stimulatory capacity of DCs to T cell proliferation,mytomycin C-treated DC were incubated with allogenic T cells.RESULTS A typical morphology of mature DCs from healthy subjects and HBV-infected patients was induced in in vitro incubation, but the proliferation ability and cellular number of DCs from HBV-infected patients significantly decreased compared with healthy individuals. In particular, the expression levels of HLADR, CD80 (B7-1) and CD86 (B7-2) on DC surface from patients were also lower than that from healthy individuals (0.46 vs 0.92 for HLA-DR, 0.44 vs 0.88 for CD80 and 0.44 vs 0. 84 for CD86, P< 0.05). The stimulatory capacity and production of IL-12 of DCs from patients in allogenic mixed lymphocyte reaction (AMLR) significantly decreased, but the production level of nitric oxide (NO) by DCa simultaneously increased compared with healthy subjects (86± 15 vs 170±22 μmoI@L 1, P<0.05).CONCLUSION The patients with chronic HBV infection have the defective function and immature phenotype of dendritic cells, which may be associated with the inability of efficient presentation of HBV antigens to host immune system for the clearance of HBV. | Fu-Sheng Wang Li-He Xing Ming-Xu Liu Chuan-Lin Zhu Hui-Gang Liu Hui-Fen Wang Zhou-Yun Lei Division of Biological Engineering,~2 Fourth Department of Liver Diseases,Beijing Institute of Infectious Diseases,Beijing Hospital of Infectious Diseases,Beijing 100039,China | 2001 | World Journal of Gastroenterology2001，7，4： | 131 |
| 2 | Isolation and initial characterization of GW5, a major QTL associated with rice grain width and weight显示文摘谷物重量是庄稼谷物产量的一个主要决定因素并且被自然地发生的量的特点 loci (QTL ) 控制。我们更早识别了控制米饭谷物宽度和重量的主要 QTL, GW5,它在米饭染色体 5 上被印射到一个再结合热点。获得 GW5 怎么控制米饭谷物宽度的更好的理解,我们进行了这个地点的好印射并且揭开在米饭栽培变种 Asominori 与增加的谷物宽度联系的 1 212-bp 删除,与苗条谷物米饭 IR24 比较。另外, 46 米饭栽培变种的 genotyping 分析表明这删除高度与谷物宽度显型被相关,建议 GW5 删除可能在米饭驯服期间被选择了。GW5 编码对原子核局部性的 144 氨基酸的新奇原子蛋白质。而且,我们证明 GW5 身体上在酵母与 polyubiquitin 交往二混血儿的试金。一起,我们的结果建议 GW5 代表主要 QTL 内在的米饭宽度和重量,并且它多半在 ubiquitin-proteasome 小径行动在种子开发期间调整房间分割。这研究提供新奇卓见进控制米饭谷物开发的分子的机制并且建议 GW5 能为庄稼的产量很高的繁殖用作一个潜在的工具。 | Jianfeng Weng Suhai Gu Xiangyuan Wan He Gao Tao Guo Ning Su Cailin Lei Xin Zhang Zhijun Cheng Xiuping Guo Jiulin Wang Ling Jiang Huqu Zhai Jianmin Wan | 2008 | Cell Research2008，18，12： | 248 |
| 3 | Fluid therapy for severe acute pancreatitis in acute response stage显示文摘为严重尖锐胰腺炎(树液) 的背景液体治疗不应该仅仅解决血体积的缺乏,而且在尖锐反应舞台阻止液体隐遁。最新,在那里,为液体治疗的策略没奉献给树液。那么,这研究被瞄准在树液的预后上调查液体治疗治疗的效果。76 个病人在 72 小时树液发作以内根据标准有希望地被招收的方法。他们随机被分到一个快速的液体扩大组(组我, n=36 ) 并且一个控制液体扩大组(组, n=40 ) 。血液动力学的混乱快速是任何一个(液体注入率是 10-15 ml 吗?? | MAO En-qiang TANG Yao-qing FEI Jian QIN Shuai WU Jun LI Lei MIN Dong ZHANG Sheng-dao | 2009 | Chinese Medical Journal2009，，2： | 89 |
| 4 | Antitumor activities of human autologous cytokineinduced killer(CIK)cells against hepatocellular carcinoma cells in vitro and in vivo显示文摘AIM: To characterize the anticancer function of cytokine-induced killer cells (CIK) and develop an adoptiveimmunotherapy for the patients with primary hepatocellularcarcinoma (HCC), we evaluated the proliferation rate,phenotype and the antitumor activity of human CIK cellsfrom healthy donors and HCC patients in vitro and in vivo.METHODS: Peripheral blood mononuclear cells (PBMC) fronhealthy donors and patients with primary HCC were incubatedin vitro and induced into ClK cells in the presence of variouscytokines such as interferon-gamma (IFN-γ), interleukin-1(IL-1), IL-2, and monoclonal antibody (mAb) against CD3.The phenotype and characterization of CIK cells wereidentified by flow cytometric analysis. The cytotoxicity of CIKcells was determined by 51 Cr release assay.RESULTS: The CIK cells were shown to be a heterogeneouspopulation with different cellular phenotypes. Thepercentage of CD3+/CD56+ positive cells, the dominanteffector cells, in total CIK cells from healthy donors andHCC patients, significantly increased from 0.1-0.13 % at day0 to 19.0-20.5 % at day 21 incubation, which suggested thatthe CD3+ CD56+ positive cells proliferated faster than othercell populations of CIK cells in the protocol used in thisstudy. After 28 day in vitro incubation, the ClK cells frompatients with HCC and healthy donors increased by morethan 300-fold and 500-fold in proliferation cell number,respectively. CIK cells originated from HCC patientspossessed a higher in vitro antitumor cytotoxic activity onautologous HCC cells than the autologous lymphokine-activated killer (LAK) cells and PBMC cells. In in vivoanimal experiment, CIK cells had stronger effects on theinhibition of tumor growth in Balb/c nude mice bearing BEL-7402-producing tumor than LAK cells (mean inhibitory rate,84.7 % vs 52.8 %, P < 0.05) or PBMC (mean inhibitoryrate, 84.7% vs37.1%, P<0.01).CONCLUSION: Autologous CIK cells are of highly efficientcytotoxic effector cells against primary hepatocellularcarcinoma cells and might serve as an alternative adoptivetherapeutic strategy for HCC patients. | Fu-Sheng Wang Ming-Xu Liu Bing Zhang Ming Shi Zhou-Yun Lei Wen-Bing Sun Qing-You Du Ju-Mei Chen,Division of Biological Engineering,Beijing Institute of Infectious Diseases,Beijing 100039,China Wen-Bing Sun,Department of Surgery,Beijing Hospital of Infectious Diseases,Beijing 100039,China | 2002 | World Journal of Gastroenterology2002，8，3： | 108 |
| 5 | Production of bioactive ginsenoside compound K in metabolically engineered yeast显示文摘 | Xing Yan Yun Fan Wei Wei Pingping Wang Qunfang Liu Yongjun Wei Lei Zhang Guoping Zhao Jianmin Yue Zhihua Zhou | 2014 | Cell Research2014，24，6： | 81 |
| 6 | Honeysuckle-encoded atypical microRNA2911 directly Largets influenza A viruses显示文摘 | Zhen Zhou Xihan Li Jinxiong Liu Lei Dong Qun Chen Jialing Liu Huihui Kongt Qianyi Zhang Xian Qi Dongxia Hou Lin Zhang Guoquan Zhang Yuchen Liu Yujing Zhang Jing Li Jin Wang Xi Chen Hua Wang Junfeng Zhang Hualan Chen Ke Zen Chen-Yu Zhang | 2015 | Cell Research2015，25，1： | 104 |
| 7 | Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative Survey显示文摘 | De-Wei Zhao Mang Yu Kai Hu Wei Wang Lei Yang Ben-Jie Wang Xiao-Hong Gao Yong-Ming Guo Yong-Qing Xu Yu-Shan Wei Si-Miao Tian Fan Yang Nan Wang Shi-Bo Huang Hui Xie Xiao-Wei Wei Hai-Shen Jiang Yu-Qiang Zang Jun Ai Yuan-Liang Chen Guang-Hua Lei Yu-Jin Li Geng Tia Zong-Sheng Li Yong Cao Li Ma | 2015 | Chinese Medical Journal2015，，21： | 151 |
| 8 | Highly fractionated granites:Recognition and research显示文摘Granite is one of the most important components of the continental crust on our Earth; it thus has been an enduring studied subject in geology. According to present knowledge, granite shows a great deal of heterogeneity in terms of its texture,structure, mineral species and geochemical compositions at different scales from small dike to large batholith. However, the reasons for these variations are not well understood although numerous interpretations have been proposed. The key point of this debate is whether granitic magma can be effectively differentiated through fractional crystallization, and, if so, what kind of crystallization occurred during the magmatic evolution. Although granitic magma has high viscosity because of its elevated SiO2 content, we agree that fractional crystallization is effectively processed during its evolution based on the evidence from field investigation,mineral species and its chemical variations, and geochemical compositions. These data indicate that crystal settling by gravitation is not the only mechanism dominating granitic differentiation. On the contrary, flow segregation or dynamic sorting may be more important. Accordingly, granite can be divided into unfractionated, fractionated(including weakly fractionated and highly fractionated) and cumulated types, according to the differentiation degree. Highly fractionated granitic magmas are generally high in primary temperature or high with various volatiles during the later stage, which make the fractional crystallization much easier than the common granitic melts. In addition, effective magmatic differentiation can be also expected when the magma emplaced along a large scale of extensional structure. Highly fractionated granitic magma is easily contaminated by country rocks due to its relatively prolonged crystallization time. Thus, granites do not always reflect the characteristics of the source areas and the physical and chemical conditions of the primary magma. We proposed that highly fractionated granites are an important sign indicating compositional maturity of the continental crust, and they are also closely related to the rare-elemental(metal) mineralization of W,Sn, Nb, Ta, Li, Be, Rb, Cs, REEs, etc. | WU FuYuan LIU XiaoChi JI WeiQiang WANG JiaMin YANG Lei | 2017 | Science China Earth Sciences2017，60，7： | 109 |
| 9 | Incidence and mortality of stomach cancer in China,2014显示文摘Objective: In this study,we aimed to estimate the updated incidence and mortality rate of stomach cancer based on the cancer registration data in 2014,collected by the National Central Cancer Registry of China(NCCRC).Methods: In 2017,339 registries' data were qualified based on the criteria of data quality control of the NCCRC.Cases of stomach cancer were retrieved from the national database.We estimated numbers of stomach cancer cases and deaths in China using age-specific rates and corresponding national population stratified by area,sex,agegroup(0,1–4,5–9,10–14,…,85+).Chinese standard population in 2000 and Segi's world population were applied for age-standardized incidence and mortality rates.Results: In 2014,410,400 new stomach cancer cases and 293,800 cancer-associated deaths were estimated to have occurred in China.The crude incidence rate of stomach cancer was 30.00/100,000,age-standardized incidence rates by Chinese standard population(ASIRC) and by world standard population(ASIRW) were 19.62/100,000 and19.51/100,000,respectively.The crude mortality rate of stomach cancer was 21.48/100,000,age-standardized mortality rates by Chinese(ASMRC) and by world standard population(ASMRW) were 13.44/100,000 and13.30/100,000,respectively.Incidence and mortality rates in rural areas were both higher than that in urban areas.Stomach cancer has a strong relationship with gender and age.The disease has occurred more frequently among men than women with a male to female ratio of 2.4 for ASIRC.After age group of 40-44 years,incidence rates are substantially higher in men than in women,same pattern was seen for age-specific mortality rates.Conclusions: There is still a heavy burden of stomach cancer in China.The incidence and mortality patterns of stomach cancer show substantial gender and regional disparities.Great effort is needed to provide more accessible health services,sufficient financial resources,and adequate cancer-care infrastructure for the Chinese population,especially for people living in rural areas. | Lei Yang Rongshou Zheng Ning Wang Yannan Yuan Shuo Liu Huichao Li Siwei Zhang Hongmei Zeng Wanqing Chen | 2018 | Chinese Journal of Cancer Research2018，30，3： | 114 |
| 10 | QTL IciMapping:Integrated software for genetic linkage map construction and quantitative trait locus mapping in biparental populations显示文摘QTL Ici Mapping is freely available public software capable of building high-density linkage maps and mapping quantitative trait loci(QTL) in biparental populations. Eight functionalities are integrated in this software package:(1) BIN: binning of redundant markers;(2) MAP: construction of linkage maps in biparental populations;(3) CMP: consensus map construction from multiple linkage maps sharing common markers;(4) SDL: mapping of segregation distortion loci;(5) BIP: mapping of additive, dominant, and digenic epistasis genes;(6) MET: QTL-by-environment interaction analysis;(7) CSL: mapping of additive and digenic epistasis genes with chromosome segment substitution lines; and(8) NAM: QTL mapping in NAM populations. Input files can be arranged in plain text, MS Excel 2003, or MS Excel 2007 formats. Output files have the same prefix name as the input but with different extensions. As examples, there are two output files in BIN, one for summarizing the identified bin groups and deleted markers in each bin, and the other for using the MAP functionality. Eight output files are generated by MAP, including summary of the completed linkage maps, Mendelian ratio test of individual markers, estimates of recombination frequencies, LOD scores, and genetic distances, and the input files for using the BIP, SDL,and MET functionalities. More than 30 output files are generated by BIP, including results at all scanning positions, identified QTL, permutation tests, and detection powers for up to six mapping methods. Three supplementary tools have also been developed to display completed genetic linkage maps, to estimate recombination frequency between two loci,and to perform analysis of variance for multi-environmental trials. | Lei Meng Huihui Li Luyan Zhang Jiankang Wang | 2015 | The Crop Journal2015，3，3： | 174 |
| 11 | Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury显示文摘The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan,Hubei province,and rapidly spread to many provinces in China as well as other countries.Here we report the epidemiological,clinical,laboratory,and radiological characteristics,as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen,China.All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).The most common laboratory abnormalities were hypoalbuminemia,lymphopenia,decreased percentage of lymphocytes (LYM) and neutrophils (NEU),elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH),and decreased CD8 count.The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity.ALB,LYM,LYM (%),LDH,NEU (%),and CRP were highly correlated to the acute lung injury.Age,viral load,lung injury score,and blood biochemistry indexes,albumin (ALB),CRP,LDH,LYM (%),LYM,and NEU (%),may be predictors of disease severity.Moreover,the Angiotensin Ⅱlevel in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury.Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection. | Yingxia Liu Yang Yang Cong Zhang Fengming Huang Fuxiang Wang Jing Yuan Zhaoqin Wang Jinxiu Li Jianming Li Cheng Feng Zheng Zhang Lifei Wang Ling Peng Li Chen Yuhao Qin Dandan Zhao Shuguang Tan Lu Yin Jun Xu Congzhao Zhou Chengyu Jiang Lei Liu | 2020 | Science China(Life Sciences)2020，63，3： | 157 |
| 12 | Future Physics Programme of BESⅢ显示文摘There has recently been a dramatic renewal of interest in hadron spectroscopy and charm physics. This renaissance has been driven in part by the discovery of a plethora of charmonium-like XYZ states at BESⅢ and B factories, and the observation of an intriguing proton-antiproton threshold enhancement and the possibly related X(1835) meson state at BESⅢ, as well as the threshold measurements of charm mesons and charm baryons. We present a detailed survey of the important topics in tau-charm physics and hadron physics that can be further explored at BESⅢ during the remaining operation period of BEPCⅡ. This survey will help in the optimization of the data-taking plan over the coming years, and provides physics motivation for the possible upgrade of BEPCⅡ to higher luminosity. | M.Ablikim M.N.Achasov P.Adlarson S.Ahmed M.Albrecht M.Alekseev A.Amoroso F.F.An Q.An Y.Bai O.Bakina R.Baldini Ferroli Y.Ban K.Begzsuren J.V.Bennett N.Berger M.Bertani D.Bettoni F.Bianchi J Biernat J.Bloms I.Boyko R.A.Briere L.Calibbi H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.Chai J.F.Chang W.L.Chang J.Charles G.Chelkov Chen G.Chen H.S.Chen J.C.Chen M.L.Chen S.J.Chen Y.B.Chen H.Y.Cheng W.Cheng G.Cibinetto F.Cossio X.F.Cui H.L.Dai J.P.Dai X.C.Dai A.Dbeyssi D.Dedovich Z.Y.Deng A.Denig Denysenko M.Destefanis S.Descotes-Genon F.De Mori Y.Ding C.Dong J.Dong L.Y.Dong M.Y.Dong Z.L.Dou S.X.Du S.I.Eidelman J.Z.Fan J.Fang S.S.Fang Y.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng M.Fritsch C.D.Fu Y.Fu Q.Gao X.L.Gao Y.Gao Y.Gao Y.G.Gao Z.Gao B.Garillon I.Garzia E.M.Gersabeck A.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl M.Greco L.M.Gu M.H.Gu Y.T.Gu A.Q.Guo F.K.Guo L.B.Guo R.P.Guo Y.P.Guo A.Guskov S.Han X.Q.Hao F.A.Harris K.L.He F.H.Heinsius T.Held Y.K.Heng Y.R.Hou Z.L.Hou H.M.Hu J.F.Hu T.Hu Y.Hu G.S.Huang J.S.Huang X.T.Huang X.Z.Huang Z.L.Huang N.Huesken T.Hussain W.Ikegami Andersson W.Imoehl M.Irshad Q.Ji Q.P.Ji X.B.Ji X.L.Ji H.L.Jiang X.S.Jiang X.Y.Jiang J.B.Jiao Z.Jiao D.P.Jin S.Jin Y.Jin T.Johansson N.Kalantar-Nayestanaki X.S.Kang R.Kappert M.Kavatsyuk B.C.Ke I.K.Keshk T.Khan A.Khoukaz P.Kiese R.Kiuchi R.Kliemt L.Koch O.B.Kolcu B.Kopf M.Kuemmel M.Kuessner A.Kupsc M.Kurth M.G.Kurth W.Kuhn J.S.Lange P.Larin L.Lavezzi H.Leithoff T.Lenz C.Li Cheng Li D.M.Li F.Li F.Y.Li G.Li H.B.Li H.J.Li J.C.Li J.W.Li Ke Li L.K.Li Lei Li P.L.Li P.R.Li Q.Y.Li W.D.Li W.G.Li X.H.Li X.L.Li X.N.Li X.Q.Li Z.B.Li H.Liang H.Liang Y.F.Liang Y.T.Liang G.R.Liao L.Z.Liao J.Libby C.X.Lin D.X.Lin Y.J.Lin B.Liu B.J.Liu C.X.Liu D.Liu D.Y.Liu F.H.Liu Fang Liu Feng Liu H.B.Liu H.M.Liu Huanhuan Liu Huihui Liu J.B.Liu J.Y.Liu K.Y.Liu Ke Liu Q.Liu S.B.Liu T.Liu X.Liu X.Y.Liu Y.B.Liu Z.A.Liu Zhiqing Liu Y.F.Long X.C.Lou H.J.Lu J.D.Lu J.G.Lu Y.Lu Y.P.Lu C.L.Luo M.X.Luo P.W.Luo T.Luo X.L.Luo S.Lusso X.R.Lyu F.C.Ma H.L.Ma L.L.Ma M.M.Ma Q.M.Ma X.N.Ma X.X.Ma X.Y.Ma Y.M.Ma F.E.Maas M.Maggiora S.Maldaner S.Malde Q.A.Malik A.Mangoni Y.J.Mao Z.P.Mao S.Marcello Z.X.Meng J.G.Messchendorp G.Mezzadri J.Min T.J.Min R.E.Mitchell X.H.Mo Y.J.Mo C.Morales Morales N.Yu.Muchnoi H.Muramatsu A.Mustafa S.Nakhoul Y.Nefedov F.Nerling I.B.Nikolaev Z.Ning S.Nisar S.L.Niu S.L.Olsen Q.Ouyang S.Pacetti Y.Pan M.Papenbrock P.Patteri M.Pelizaeus H.P.Peng K.Peters A.A.Petrov J.Pettersson J.L.Ping R.G.Ping A.Pitka R.Poling V.Prasad M.Qi T.Y.Qi S.Qian C.F.Qiao N.Qin X.P.Qin X.S.Qin Z.H.Qin J.F.Qiu S.Q.Qu K.H.Rashid C.F.Redmer M.Richter M.Ripka A.Rivetti V.Rodin M.Rolo G.Rong J.L.Rosner Ch.Rosner M.Rump A.Sarantsev M.Savrie K.Schoenning W.Shan X.Y.Shan M.Shao C.P.Shen P.X.Shen X.Y.Shen H.Y.Sheng X.Shi X.D Shi J.J.Song Q.Q.Song X.Y.Song S.Sosio C.Sowa S.Spataro F.F.Sui G.X.Sun J.F.Sun L.Sun S.S.Sun X.H.Sun Y.J.Sun Y.K Sun Y.Z.Sun Z.J.Sun Z.T.Sun Y.T Tan C.J.Tang G.Y.Tang X.Tang V.Thoren B.Tsednee I.Uman B.Wang B.L.Wang C.W.Wang D.Y.Wang H.H.Wang K.Wang L.L.Wang L.S.Wang M.Wang M.Z.Wang Wang Meng P.L.Wang R.M.Wang W.P.Wang X.Wang X.F.Wang X.L.Wang Y.Wang Y.F.Wang Z.Wang Z.G.Wang Z.Y.Wang Zongyuan Wang T.Weber D.H.Wei P.Weidenkaff H.W.Wen S.P.Wen U.Wiedner G.Wilkinson M.Wolke L.H.Wu L.J.Wu Z.Wu L.Xia Y.Xia S.Y.Xiao Y.J.Xiao Z.J.Xiao Y.G.Xie Y.H.Xie T.Y.Xing X.A.Xiong Q.L.Xiu G.F.Xu L.Xu Q.J.Xu W.Xu X.P.Xu F.Yan L.Yan W.B.Yan W.C.Yan Y.H.Yan H.J.Yang H.X.Yang L.Yang R.X.Yang S.L.Yang Y.H.Yang Y.X.Yang Yifan Yang Z.Q.Yang M.Ye M.H.Ye J.H.Yin Z.Y.You B.X.Yu C.X.Yu J.S.Yu C.Z.Yuan X.Q.Yuan Y.Yuan A.Yuncu A.A.Zafar Y.Zeng B.X.Zhang B.Y.Zhang C.C.Zhang D.H.Zhang H.H.Zhang H.Y.Zhang J.Zhang J.L.Zhang J.Q.Zhang J.W.Zhang J.Y.Zhang J.Z.Zhang K.Zhang L.Zhang S.F.Zhang T.J.Zhang X.Y.Zhang Y.Zhang Y.H.Zhang Y.T.Zhang Yang Zhang Yao Zhang Yi Zhang Yu Zhang Z.H.Zhang Z.P.Zhang Z.Q.Zhang Z.Y.Zhang G.Zhao J.W.Zhao J.Y.Zhao J.Z.Zhao Lei Zhao Ling Zhao M.G.Zhao Q.Zhao S.J.Zhao T.C.Zhao Y.B.Zhao Z.G.Zhao A.Zhemchugov B.Zheng J.P.Zheng Y.Zheng Y.H.Zheng B.Zhong L.Zhou L.P.Zhou Q.Zhou X.Zhou X.K.Zhou Xingyu Zhou Xiaoyu Zhou Xu Zhou A.N.Zhu J.Zhu J.Zhu K.Zhu K.J.Zhu S.H.Zhu W.J.Zhu X.L.Zhu Y.C.Zhu Y.S.Zhu Z.A.Zhu J.Zhuang B.S.Zou J.H.Zou 无 | 2020 | Chinese Physics C2020，44，4： | 517 |
| 13 | Th e role of ferroptosis in ionizing radiation-induced cell death and tumor suppression显示文摘Ferroptosis,a form of regulated cell death caused by lipid peroxidation,was recently identified as a natural tumor suppression mechanism.Here,we show that ionizing radiation(IR)induces ferroptosis in cancer cells.Mechanistically,IR induces not only reactive oxygen species(ROS)but also the expression of ACSL4,a lipid metabolism enzyme required for ferroptosis,resulting in elevated lipid peroxidation and ferroptosis.ACSL4 ablation largely abolishes IR-induced ferroptosis and promotes radioresistance.IR also induces the expression of ferroptosis inhibitors,including SLC7A11 and GPX4;as an adaptive response.IR-or KEAP1 deficiencyinduced SLC7A11 expression promotes radioresistance through inhibiting ferroptosis.Inactivating SLC7A11 or GPX4 with ferroptosis inducers(FINs)sensitizes radioresistant cancer cells and xenograft tumors to IR.Furthermore,radiotherapy induces ferroptosis in cancer patients,and increased ferroptosis correlates with better response and longer survival to radiotherapy in cancer patients.Our study reveals a previously unrecognized link between IR and ferroptosis and indicates that further exploration of the combination of radiotherapy and FINs in cancer treatment is warranted. | Guang Lei Yilei Zhang Pranavi Koppula Xiaoguang Liu Jie Zhang Steven HLin Jaffer AAjani Qin Xiao Zhongxing Liao Hui Wang Boyi Gan | 2020 | Cell Research2020，30，2： | 88 |
| 14 | The Chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer显示文摘China is one of the countries with the highest incidence of gastric cancer.There are differences in epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selection between gastric cancer patients from the Eastern and Western countries.Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients.The Chinese Society of Clinical Oncology(CSCO)arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile,discuss,and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad.By referring to the opinions of industry experts,taking into account of regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted experts’consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes.This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis,comprehensive treatment,and follow-up visits for gastric cancer. | Feng-Hua Wang Lin Shen Jin Li Zhi-Wei Zhou Han Liang Xiao-Tian Zhang Lei Tang Yan Xin Jing Jin Yu-Jing Zhang Xiang-Lin Yuan Tian-Shu Liu Guo-Xin Li Qi Wu Hui-Mian Xu Jia-Fu Ji Yuan-Fang Li Xin Wang Shan Yu Hao Liu Wen-Long Guan Rui-Hua Xu | 2019 | Cancer Communications2019，39，1： | 127 |
| 15 | The Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021显示文摘There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western countries.The Chinese Society of Clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually.Taking into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China.The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis,treatment,follow-up,and screening of gastric cancer.Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from China and overseas for the past year,focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations.For the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant treatment.The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated.For the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided. | Feng-Hua Wang Xiao-Tian Zhang Yuan-Fang Li Lei Tang Xiu-Juan Qu Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Hong Qiu Chang Wang Miao-Zhen Qiu Mu-Yan Cai QiWu Hao Liu Wen-Long Guan Ai-Ping Zhou Yu-Jing Zhang Tian-Shu Liu Feng Bi Xiang-Lin Yuan Sheng-Xiang Rao Yan Xin Wei-Qi Sheng Hui-Mian Xu Guo-Xin Li Jia-Fu Ji Zhi-Wei Zhou Han Liang Yan-Qiao Zhang Jing Jin Lin Shen Jin Li Rui-Hua Xu | 2021 | Cancer Communications2021，41，8： | 97 |
| 16 | A complete sequence and comparative analysis of a SARS-associated virus(Isolate BJ01)显示文摘The genome sequence of the Severe Acute Respiratory Syndrome (SARS)-associated virus provides essential information for the identification of pathogen(s), exploration of etiology and evolution, interpretation of transmission and pathogenesis, development of diagnostics, prevention by future vaccination, and treatment by developing new drugs. We report the complete genome sequence and comparative analysis of an isolate (BJ01) of the coronavirus that has been recognized as a pathogen for SARS. The genome is 29725 nt in size and has 11 ORFs (Open Reading Frames). It is composed of a stable region encoding an RNA-dependent RNA polymerase (composed of 2 ORFs) and a variable region representing 4 CDSs (coding sequences) for viral structural genes (the S, E, M, N proteins) and 5 PUPs (putative uncharacterized proteins). Its gene order is identical to that of other known coronaviruses. The sequence alignment with all known RNA viruses places this virus as a member in the family of Coronaviridae. Thirty putative substitutions have been identified by comparative analysis of the 5 SARS- associated virus genome sequences in GenBank. Fifteen of them lead to possible amino acid changes (non-synonymous mutations) in the proteins. Three amino acid changes, with predicted alteration of physical and chemical features, have been detected in the S protein that is postulated to beinvolved in the immunoreactions between the virus and its host. Two amino acid changes have been detected in the Mprotein, which could be related to viral envelope formation. Phylogenetic analysis suggests the possibility of non-human origin of the SARS-associated viruses but provides noevidence that they are man-made. Further efforts should focus on identifying the etiology of the SARS-associated virus and ruling out conclusively the existence of otherpossible SARS-related pathogen(s). | QIN E'de ZHU Qingyu YU Man FAN Baochang CHANG Guohui SI Bingyin YANG Bao PENG Wenming JIANG Tao LIU Bohua DENG Yongqiang LIU Hong ZHANG Yu WANG Cui LI Yuquan GAN Yonghua LI Xiaoyu L Fushuang TAN Gang CAO Wuchun, YANG Ruifu Institute of Microbiology and Epidemiology, Chinese Academy of Military Medical Sciences, Beijing 100071, China WANG Jian, LI Wei, XU Zuyuan, LI Yan, WU Qingfa, LIN Wei, CHEN Weijun, TANG Lin, DENG Yajun, HAN Yujun, LI Changfeng, LEI Meng, LI Guoqing, LI Wenjie, L Hong, SHI Jianping, TONG Zongzhong, ZHANG Feng, LI Songgang, LIU Bin, LIU Siqi, DONG Wei, WANG Jun, Gane K-S Wong, YU Jun & YANG Huanming* Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300 National Center for Genome Information, Beijing 101300, China | 2003 | Chinese Science Bulletin2003，48，10： | 121 |
| 17 | Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets显示文摘Liver fibrosis is a reversible wound-healing process aimed at maintaining organ integrity, and presents as the critical pre-stage of liver cirrhosis, which will eventually progress to hepatocellular carcinoma in the absence of liver transplantation. Fibrosis generally results from chronic hepatic injury caused by various factors, mainly viral infection, schistosomiasis, and alcoholism; however, the exact pathological mechanisms are still unknown. Although numerous drugs have been shown to have antifibrotic activity in vitro and in animal models, none of these drugs have been shown to be efficacious in the clinic. Importantly, hepatic stellate cells(HSCs) play a key role in the initiation, progression, and regression of liver fibrosis by secreting fibrogenic factors that encourage portal fibrocytes, fibroblasts, and bone marrow-derived myofibroblasts to produce collagen and thereby propagate fibrosis. These cells are subject to intricate cross-talk with adjacent cells, resulting in scarring and subsequent liver damage. Thus, an understanding of the molecular mechanisms of liver fibrosis and their relationships with HSCs is essential for the discovery of new therapeutic targets. This comprehensive review outlines the role of HSCs in liver fibrosis and details novel strategies to suppress HSC activity, thereby providing new insights into potential treatments for liver fibrosis. | Chong-Yang Zhang Wei-Gang Yuan Pei He Jia-Hui Lei Chun-Xu Wang | 2016 | World Journal of Gastroenterology2016，22，48： | 114 |
| 18 | Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors显示文摘 | Jing Liao Zhao Wu Ying Wang Lu Cheng Chun Cui Yuan Gao Taotao Chen Lingjun Rao Siye Chen Nannan Jia Huiming Dai Shunmei Xin Jiuhong Kang Gang Pei Lei Xiao | 2008 | Cell Research2008，18，5： | 61 |
| 19 | Hypoxla inducible factor 1 (HIF-1) and cardioprotection显示文摘 | Demet TEKIN Ali D DURSUN Lei XI | 2010 | Acta Pharmacologica Sinica2010，31，9： | 62 |
| 20 | A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus显示文摘AIM:To determine the therapeutic effect of lamivudine in late pregnancy for the interruption of motherto-child transmission(MTCT) of hepatitis B virus(HBV).METHODS:Studies were identified by searching available databases up to January 2011.Inclusive criteria were HBV-carrier mothers who had been involved in randomized controlled clinical trials(RCTs) with lamivudine treatment in late pregnancy,and newborns or infants whose serum hepatitis B surface antigen(HBsAg),hepatitis B e antigen(HBeAg) or HBV DNA had been documented.The relative risks(RRs) for interruption of MTCT as indicated by HBsAg,HBV DNA or HBeAg of newborns or infants were calculated with 95% confidence interval(CI) to estimate the efficacy of lamivudine treatment.RESULTS:Fifteen RCTs including 1693 HBV-carrier mothers were included in this meta-analysis.The overall RR was 0.43(95% CI,0.25-0.76;8 RCTs;Pheterogeneity = 0.04) and 0.33(95% CI,0.23-0.47;6 RCTs;Pheterogeneity = 0.93) indicated by newborn HBsAg or HBV DNA.The RR was 0.33(95% CI,0.21-0.50;6 RCTs;Pheterogeneity = 0.46) and 0.32(95% CI,0.20-0.50;4 RCTs;Pheterogeneity = 0.33) indicated by serum HBsAg or HBV DNA of infants 6-12 mo after birth.The RR(lamivudine vs hepatitis B immunoglobulin) was 0.27(95% CI,0.16-0.46;5 RCTs;Pheterogeneity = 0.94) and 0.24(95% CI,0.07-0.79;3 RCTs;P heterogeneity = 0.60) indicated by newborn HBsAg or HBV DNA,respectively.In the mothers with viral load < 106 copies/mL after lamivudine treatment,the efficacy(RR,95% CI) was 0.33,0.21-0.53(5 RCTs;Pheterogeneity = 0.82) for the interruption of MTCT,however,this value was not significant if maternal viral load was > 106 copies/mL after lamivudine treatment(P = 0.45,2 RCTs),as indicated by newborn serum HBsAg.The RR(lamivudine initiated from 28 wk of gestation vs control) was 0.34(95% CI,0.22-0.52;7 RCTs;Pheterogeneity = 0.92) and 0.33(95% CI,0.22-0.50;5 RCTs;Pheterogeneity = 0.86) indicated by newborn HBsAg or HBV DNA.The incidence of adverse effects of lamivudine was not higher in the mothers than in controls(P = 0.97).Only one study reported side effects of lamivudine in newborns.CONCLUSION:Lamivudine treatment in HBV carriermothers from 28 wk of gestation may interrupt MTCT of HBV efficiently.Lamivudine is safe and more efficient than hepatitis B immunoglobulin in interrupting MTCT.HBV MTCT might be interrupted efficiently if maternal viral load is reduced to < 106 copies/mL by lamivudine treatment. | Lei Han Hong-Wei Zhang Jia-Xin Xie Qi Zhang Hong-Yang Wang Guang- Wen Cao | 2011 | World Journal of Gastroenterology2011，17，38： | 61 |
您所在的机构暂未开通此部分的功能，请联系管理员